China completed preliminary studies have two new anti-drugs into the clinical crown
Since the new crown pneumonia outbreak, medical treatment in our country continue to study and explore effective treatment, we embarked on a new crown anti-viral drug research and development. Recently, the Science and Technology Daily reporter learned from the CAS Shanghai Institute of Materia Medica, both developed by the Institute to participate in the new anti-drugs crown has completed preclinical studies and clinical trials.
"At present, two new anti-drugs are the crown were completed preclinical studies, clinical studies in many countries, if through clinical stage Ⅰ, Ⅱ stage, Ⅲ of verification confirmed the efficacy of the new crown will benefit patients around the world." Chinese Academy of Sciences Shanghai director of the Institute of Pharmacology Gilbert said in an interview.
New drug candidates oral anti-viral crown VV116 VV116 permitted to conduct clinical trials, the Chinese Academy of Sciences and Chinese Academy of Sciences Institute of Virology, Wuhan Institute of Physics and Chemistry, Xinjiang and other technical domestic research institutes jointly developed by the Shanghai Institute of Materia Medica Chinese Academy of Sciences of Ukraine in an oral nucleoside The new crown anti-viral drug candidates.
Preclinical studies show efficacy, VV116 new crown original virus strains and mutants, for example, are inhibited in vitro Delta virus significant activity role, it is expected to become a variety of means, including the fight against SARS vaccine, antibody drugs, including the strong complementary. Shanghai Institute of Materia Medica Chinese Academy of Sciences researcher Shen Jing Shan research team and research institutions through cooperation on the model of adenovirus in mice trials found that oral VV116 viral titers can be reduced to below the detection limit, can significantly improve the pathological changes in experimental animal models of lung tissue.
"A series of preclinical safety evaluation experiments showed that the safety VV116 better and no genetic toxicity.
"Shen Jing Shan said. Shen Jing Shan researcher, at present, VV116 drug candidate has been fully completed pre-clinical studies, first in Uzbekistan allowed to carry out clinical 上海品茶微信群 trials, the clinical trial stage Ⅰ, Ⅱ stage, Ⅲ of simultaneously carried out.
Innovative drugs FB2001 has been Ⅰ clinical study in the United States new crown another anti-viral drug candidates FB2001 is also intense study.
FB2001 jointly developed by the Chinese Academy of Sciences Shanghai Institute of Materia Medica, Shanghai University of Science and Technology and the Chinese Academy of Sciences Institute of Virology, Wuhan and other units.
Hong Liu, head of the research group researcher told reporters that they were innovative drug research focused on new crown viral replication cycle is a very important target –3CL proteolytic enzymes, FB2001 they found from the experiment one active compound, "FB2001 has very good inhibition of enzyme activity, but also has good antiviral effect 上海宝山罗店有小巷子 on the crown of the new virus. "relevant research results have been published in" the journal Science. "
The drug candidate has won in August 2020, the US FDA approved clinical trials, I clinical study in March 2021 and was officially launched in the United States, single-center, randomized, blinded, controlled design, the main purpose for the evaluation of this product tolerance in humans, safety and pharmacokinetic characteristics.
The drugs currently administered 5mg, 15mg, 30mg3 dose groups has been completed, preliminary results show, FB2001 show a favorable safety and pharmacokinetic characteristics of the human body. It is understood that R & D work for the new crown anti-viral drugs, the CAS Shanghai Institute of Materia Medica has been building in the screening system, virtual 上海油压 screening, high-throughput screening, discovery of lead compounds and subsequent development of small molecule drug candidates have made good progress.